Sentence examples for morphological imaging techniques from inspiring English sources

Molecular imaging (MI) includes a number of morphological imaging techniques (i.e. ultrasound, computed tomography and magnetic resonance imaging), and optical imaging techniques (i.e. bioluminescence and fluorescence imaging) [3, 4].

Together with morphological imaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI), it has become an important tool for tumour visualization, staging, and evaluation of somatostatin receptor status [9].

This limits the traditional morphological imaging techniques, which emphasize the quantification simply of structural information.

Different morphological imaging techniques have been used to facilitate the intraoperative localization.

Different morphological imaging techniques have been used to facilitate intra-operative localization.

Infiltrative, progressive tumour growth is often associated with distortion of anatomical lead structures and therefore inflicting restrictions to morphological imaging techniques.

Correct diagnoses are still associated with difficulties, especially when only morphological imaging technique is performed [ 32].

The development of morphological and functional imaging techniques has improved the diagnosis of muscular disorders.

By using the overlay technique, it is possible to correlate pathologic features imaged with familiar transversal imaging techniques, such FA, with the morphological information provided on OCT C-scans.

Moreover, its diagnostic accuracy for the detection of carcinoids [31, 37] and phaeochromocytoma [31, 36] was shown to be higher than that of other imaging techniques, both morphological (including CT/MRI) and functional (123I-MIBG and 111In-Octreoscan) [31, 38].

Furthermore, imaging techniques integrating a morphological and functional assessment such as IVUS, OCT, PET/CT and PET/MRI may represent in a near future robust "soft" endpoints to support successful translation of early research into meaningful phase III clinical outcome trials.